- Home
- RLI vs NUVL Comparison
RLI vs NUVL Comparison
Compare RLI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLI
- NUVL
- Stock Information
- Founded
- RLI 1965
- NUVL 2017
- Country
- RLI United States
- NUVL United States
- Employees
- RLI N/A
- NUVL 200
- Industry
- RLI Property-Casualty Insurers
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- RLI Finance
- NUVL Health Care
- Exchange
- RLI Nasdaq
- NUVL Nasdaq
- Market Cap
- RLI 6.1B
- NUVL 6.0B
- IPO Year
- RLI 1985
- NUVL 2021
- Fundamental
- Price
- RLI $65.10
- NUVL $83.50
- Analyst Decision
- RLI Hold
- NUVL Strong Buy
- Analyst Count
- RLI 8
- NUVL 9
- Target Price
- RLI $75.83
- NUVL $118.89
- AVG Volume (30 Days)
- RLI 617.4K
- NUVL 396.7K
- Earning Date
- RLI 10-20-2025
- NUVL 11-11-2025
- Dividend Yield
- RLI 4.09%
- NUVL N/A
- EPS Growth
- RLI N/A
- NUVL N/A
- EPS
- RLI 3.50
- NUVL N/A
- Revenue
- RLI $1,816,602,000.00
- NUVL N/A
- Revenue This Year
- RLI N/A
- NUVL N/A
- Revenue Next Year
- RLI $4.05
- NUVL N/A
- P/E Ratio
- RLI $18.42
- NUVL N/A
- Revenue Growth
- RLI 11.69
- NUVL N/A
- 52 Week Low
- RLI $62.04
- NUVL $55.54
- 52 Week High
- RLI $91.15
- NUVL $106.32
- Technical
- Relative Strength Index (RSI)
- RLI 45.68
- NUVL 55.05
- Support Level
- RLI $62.04
- NUVL $81.02
- Resistance Level
- RLI $65.23
- NUVL $86.34
- Average True Range (ATR)
- RLI 1.11
- NUVL 3.63
- MACD
- RLI 0.04
- NUVL 0.25
- Stochastic Oscillator
- RLI 67.38
- NUVL 62.11
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.